SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gran JT, Husby G. Epidemiology of ankylosing spondylitis. In: HochbergMC, SilmanAJ, SmolenJS, WeinblattME, WeismanMH, editors. Rheumatology. 3rd ed. Volume 2. Edinburgh: Mosby; 2003. p. 11539.
  • 2
    Dagfinrud H, Mengshoel AM, Hagan KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 2004; 63: 160510.
  • 3
    Bostan EE, Borman P, Bodur H, Barca N. Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 1216.
  • 4
    Zink A, Braun J, Listing J, Wollenhaupt J, for the German Collaborative Arthritis Centers. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. J Rheumatol 2000; 27: 61322.
  • 5
    Ward MM. Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 1998; 24: 81527.
  • 6
    Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: a comparison of three European countries. Ann Rheum Dis 2002; 61: 42937.
  • 7
    Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis: a systematic literature review. J Rheumatol 2001; 28: 105662.
  • 8
    Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499505.
  • 9
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 44252.
  • 10
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Toah LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 140011.
  • 11
    Furst DE, Schiff LM, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti–tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 256371.
  • 12
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–TNF-α monoclonal antibody, for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA Trial. Arthritis Rheum 2003; 48: 3545.
  • 13
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 327989.
  • 14
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab for patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial (ATLAS). Arthritis Rheum 2006; 54: 213646.
  • 15
    Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 32306.
  • 16
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 58291.
  • 17
    Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002; 41: 1295302.
  • 18
    Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494501.
  • 19
    Da Costa D, Dritsa M, Ring A, Fitzcharles MA. Mental health status and leisure-time physical activity contribute to fatigue intensity in patients with spondylarthropathy. Arthritis Rheum 2004; 51: 10048.
  • 20
    Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Global Score (BAS-G). Br J Rheumatol 1996; 35: 6671.
  • 21
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 22
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 23
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for shortterm improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 143844.
  • 24
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 25
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 26
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol 1994; 21: 16948.
  • 27
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 11327.
  • 28
    Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887900.
  • 29
    Ware JE Jr, Snow KK, Kosinski M. SF-36 Health Survey: manual and interpretation guide. Lincoln (RI): Quality Metric Inc.; 2000.
  • 30
    Ware JE, Kosinski M, Keller S. SF-36 physical and mental health summary scores: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
  • 31
    Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 1246.
  • 32
    Chorus AM, Miedema HS, Boonen A, van der Linden SJ. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003; 62: 117884.
  • 33
    Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002; 8: 23140.
  • 34
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 7: 147887.
  • 35
    Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 206.
  • 36
    Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the patient generated index. J Rheumatol 2003; 30: 76473.
  • 37
    Fairclough DL. Design and analysis of quality of life studies in clinical trials. Boca Raton: Chapman & Hall/CRC; 2002.
  • 38
    Van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002; 47: 816.
  • 39
    Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 21127.
  • 40
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 118793.